Silver Book Fact

An oral cannabinoid was found effective in relieving diabetic peripheral neuropathic pain symptoms and improving disturbed sleep, quality of life, and overall patient status.

Toth, Croy, Shefina Mawani, Shauna Brady, Cynthia Chan, CaiXia Liu, Essie Mehina, Alexandra Garvan, Jennifer Bestard, and Lawrence Korngut. An Enriched-Enrollment, Randomized Withdrawal, Flexible-Dose, Double-Blind, Placebo-Controlled, Parallel Assignment Efficacy Study of Nabilone as Adjuvant in the Treatment of Diabetic Peripheral Neuropathic Pain. Pain. 2012; 153(10): 2073-82. http://journals.lww.com/pain/Abstract/2012/10000/An_enriched_enrolment,_randomized_withdrawal,.16.aspx

Reference

Title
An Enriched-Enrollment, Randomized Withdrawal, Flexible-Dose, Double-Blind, Placebo-Controlled, Parallel Assignment Efficacy Study of Nabilone as Adjuvant in the Treatment of Diabetic Peripheral Neuropathic Pain
Publication
Pain
Publication Date
2012
Authors
Toth, Croy, Shefina Mawani, Shauna Brady, Cynthia Chan, CaiXia Liu, Essie Mehina, Alexandra Garvan, Jennifer Bestard, and Lawrence Korngut
Volume & Issue
Volume 153, Issue 10
Pages
2073-82
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord…  
  • People with persistent pain who used complementary and alternative medicine (CAM) had lower average health care expenditures than nonusers ($3,797 versus $4,153).  
  • An opiate agonist often used for persistent pain, tramadol was found in one meta-analysis to significantly reduce neuropathic pain when compared to placebo.  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • Use of stem cells to create neurons could enable the study of the response of human cells to new drugs in vitro, early in the drug development process.